Accurexa Inc. (ACXA) 0.9000 $ACXA
Accurexa's First "New To The Street" Interview on YouTube
ACCESSWIRE - Mon Apr 06, 6:15PM CDT
SAN FRANCISCO, CA / ACCESSWIRE / April 6, 2015 / Accurexa Inc. (the "Company"
(OTCQB:ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that its first "New To The Street" interview was aired nationwide and is available on YouTube under the following link (https://www.youtube.com/watch?v=7tUYtz7WV2U).
Accurexa's BranchPoint Demonstrates Feasibility of Convection-Enhanced Delivery
ACCESSWIRE - Mon Mar 23, 7:01AM CDT
SAN FRANCISCO, CA / ACCESSWIRE / March 23, 2015 / Accurexa Inc. (the "Company" (OTCQB:ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, reported that its BranchPoint technology has been tested for its ability to deploy a Convection-Enhanced Delivery (CED) catheter that is compatible for use with intraoperative Magnetic Resonance Imaging (iMRI) guidance. This feasibility testing of CED with the BranchPoint technology supports the Company's ACX-31 development program which could deliver temozolomide, a chemotherapy drug, directly to the tumor site with the Company's BranchPoint device. Temozolomide is a generic, approved chemotherapy drug that is indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. Before temozolomide became generic, it generated US sales of $420 million and global sales of $910 million under its brand name Temodar in 2012.
"New To The Street" to Air First of a 6 Part Series Featuring Accurexa, Inc. (ACXA)
Marketwired - Wed Mar 18, 9:49AM CDT
"New To The Street" just completed a full 11 minute in-depth interview with George Yu, President and CEO of Accurexa Inc. (OTCQB: ACXA) and its BranchPoint Device.
DSKX: 2.18 (+0.23)
FDA Approves Accurexa's Small Business Qualification
ACCESSWIRE - Mon Mar 16, 7:03AM CDT
SAN FRANCISCO, CA / ACCESSWIRE / March 16, 2015 / Accurexa Inc. (the "Company" (OTCQB:ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that the U.S. FDA (Food and Drug Administration) informed the Company that it qualifies under MDUFA (Medical Device User Fee Amendment) as a Small Business for a reduced or waived fee for medical device submissions made during fiscal year 2015. The Company's Small Business status expires at the close of business September 30, 2015.
Accurexa's Licensed Patent Application Enters National Phase
ACCESSWIRE - Mon Mar 09, 7:01AM CDT
SAN FRANCISCO, CA / ACCESSWIRE / March 9, 2015 / Accurexa Inc. (the "Company" (OTCQB:ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that the U.S. Patent Application No. PCT/US2013/052301, Microinjection Catheter; UC Case No. SF2012-063, which the Company exclusively licensed from the University of California, San Francisco (UCSF), has entered national phase applications in the US, European Union, Japan, Canada and China.
Accurexa's BranchPoint Device Delivering Dopaminergic Stem Cells Published in Molecular Therapy
ACCESSWIRE - Thu Feb 12, 7:00AM CST
SAN FRANCISCO, CA / ACCESSWIRE / February 12, 2015 / Accurexa Inc. (the "Company" (OTCQB: ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that its BranchPoint device was published in a scientific publication in Molecular Therapy, the official journal of the American Society for Gene & Cell Therapy. Accurexa's BranchPoint device successfully demonstrated the feasibility of delivering human embryonic stem cell-derived dopaminergic neurons in a large animal study. BranchPoint's intracerebral cell transplantation deployed cells to multiple target locations at variable radial distances and depths along the initial brain penetration tract with real-time interventional magnetic resonance image (iMRI) guidance, which can be critical in the treatment of Parkinson's Disease.
Accurexa Initiates Development of Chemotherapy Product for Brain Cancer
ACCESSWIRE - Wed Feb 04, 7:31AM CST
SAN FRANCISCO,CA / ACCESSWIRE / February 4, 2015 / Accurexa Inc. (the "Company" (OTCQB: ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that it initiated the development of ACX-31 for the treatment of glioblastoma multiforme, a malignant primary brain tumor. ACX-31 is a chemotherapy product that delivers temozolomide directly to the tumor site with the Company's BranchPoint device. Temozolomide is a generic, approved chemotherapy drug that is indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. The Company's BrainPoint device has been developed for the delivery of therapeutics directly into specific regions of the brain and is expected to obtain FDA regulatory approval through a 510(k) submission process.
Arrowhead Business and Investment Decisions Initiates Coverage on Accurexa Inc.
ACCESSWIRE - Thu Jan 22, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / January 22, 2015 / Arrowhead Business and Investment Decisions, LLC ("Arrowhead" initiated coverage and published a Due Diligence and Valuation Report on Accurexa Inc. ("Accurexa" or the "Company" (OTCQB:ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, on December 23, 2014.
Accurexa Announces Appointment of Daniel A. Lim MD, PhD to its Scientific Advisory Board
ACCESSWIRE - Tue Jan 13, 7:00AM CST
SAN FRANCISCO, CA / ACCESSWIRE / January 13, 2015 / Accurexa Inc. (the "Company" (OTCQB: ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today the appointment of Daniel A. Lim MD, PhD to its newly formed Scientific Advisory Board. The Scientific Advisory Board will work closely with the Company's management in the development of novel neurological therapies based on the Company's proprietary BranchPoint technology delivering therapeutics directly into specific regions of the brain.
Accurexa to Present at 2014 Stem Cell Meeting on the Mesa
ACCESSWIRE - Mon Sep 29, 7:00AM CDT
San Francisco, California / ACCESSWIRE / September 29, 2014 / Accurexa Inc. (the "Company" (OTCQB: ACXA) announced today that George Yu, the Company's President & CEO, will co-present with Daniel Lim, M.D., Ph.D., Assistant Professor of Neurological Surgery, University of California, San Francisco (UCSF) at the 4th Annual Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, CA.
Accurexa Announces Exclusive License Agreement With Uc San Francisco
ACCESSWIRE - Wed Sep 17, 8:16AM CDT
SAN FRANCISCO, CA / ACCESSWIRE / September 17, 2014 / Accurexa Inc. (the "Company" (OTCQB: ACXA) announced today that it has entered into an exclusive license agreement (the "UCSF License" with the University of California, San Francisco ("UCSF" in regards to the exclusive global licensing of a medical stereotactic device (the "UCSF device" , which the Company believes has the potential to significantly improve the delivery of stem cells into the human brain and enhance the efficacy of a wide range of stem cell therapeutics. Beyond stem cells, the platform technology of the UCSF device can also enable the delivery of cell-based therapeutics, gene therapies, and traditional drugs and drug infusions into the human brain.
Accurexa's First "New To The Street" Interview on YouTube
ACCESSWIRE - Mon Apr 06, 6:15PM CDT
SAN FRANCISCO, CA / ACCESSWIRE / April 6, 2015 / Accurexa Inc. (the "Company"
(OTCQB:ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that its first "New To The Street" interview was aired nationwide and is available on YouTube under the following link (https://www.youtube.com/watch?v=7tUYtz7WV2U). Accurexa's BranchPoint Demonstrates Feasibility of Convection-Enhanced Delivery
ACCESSWIRE - Mon Mar 23, 7:01AM CDT
SAN FRANCISCO, CA / ACCESSWIRE / March 23, 2015 / Accurexa Inc. (the "Company"
(OTCQB:ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, reported that its BranchPoint technology has been tested for its ability to deploy a Convection-Enhanced Delivery (CED) catheter that is compatible for use with intraoperative Magnetic Resonance Imaging (iMRI) guidance. This feasibility testing of CED with the BranchPoint technology supports the Company's ACX-31 development program which could deliver temozolomide, a chemotherapy drug, directly to the tumor site with the Company's BranchPoint device. Temozolomide is a generic, approved chemotherapy drug that is indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. Before temozolomide became generic, it generated US sales of $420 million and global sales of $910 million under its brand name Temodar in 2012. "New To The Street" to Air First of a 6 Part Series Featuring Accurexa, Inc. (ACXA)
Marketwired - Wed Mar 18, 9:49AM CDT
"New To The Street" just completed a full 11 minute in-depth interview with George Yu, President and CEO of Accurexa Inc. (OTCQB: ACXA) and its BranchPoint Device.
DSKX: 2.18 (+0.23)
FDA Approves Accurexa's Small Business Qualification
ACCESSWIRE - Mon Mar 16, 7:03AM CDT
SAN FRANCISCO, CA / ACCESSWIRE / March 16, 2015 / Accurexa Inc. (the "Company"
(OTCQB:ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that the U.S. FDA (Food and Drug Administration) informed the Company that it qualifies under MDUFA (Medical Device User Fee Amendment) as a Small Business for a reduced or waived fee for medical device submissions made during fiscal year 2015. The Company's Small Business status expires at the close of business September 30, 2015. Accurexa's Licensed Patent Application Enters National Phase
ACCESSWIRE - Mon Mar 09, 7:01AM CDT
SAN FRANCISCO, CA / ACCESSWIRE / March 9, 2015 / Accurexa Inc. (the "Company"
(OTCQB:ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that the U.S. Patent Application No. PCT/US2013/052301, Microinjection Catheter; UC Case No. SF2012-063, which the Company exclusively licensed from the University of California, San Francisco (UCSF), has entered national phase applications in the US, European Union, Japan, Canada and China. Accurexa's BranchPoint Device Delivering Dopaminergic Stem Cells Published in Molecular Therapy
ACCESSWIRE - Thu Feb 12, 7:00AM CST
SAN FRANCISCO, CA / ACCESSWIRE / February 12, 2015 / Accurexa Inc. (the "Company"
(OTCQB: ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that its BranchPoint device was published in a scientific publication in Molecular Therapy, the official journal of the American Society for Gene & Cell Therapy. Accurexa's BranchPoint device successfully demonstrated the feasibility of delivering human embryonic stem cell-derived dopaminergic neurons in a large animal study. BranchPoint's intracerebral cell transplantation deployed cells to multiple target locations at variable radial distances and depths along the initial brain penetration tract with real-time interventional magnetic resonance image (iMRI) guidance, which can be critical in the treatment of Parkinson's Disease. Accurexa Initiates Development of Chemotherapy Product for Brain Cancer
ACCESSWIRE - Wed Feb 04, 7:31AM CST
SAN FRANCISCO,CA / ACCESSWIRE / February 4, 2015 / Accurexa Inc. (the "Company"
(OTCQB: ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that it initiated the development of ACX-31 for the treatment of glioblastoma multiforme, a malignant primary brain tumor. ACX-31 is a chemotherapy product that delivers temozolomide directly to the tumor site with the Company's BranchPoint device. Temozolomide is a generic, approved chemotherapy drug that is indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. The Company's BrainPoint device has been developed for the delivery of therapeutics directly into specific regions of the brain and is expected to obtain FDA regulatory approval through a 510(k) submission process. Arrowhead Business and Investment Decisions Initiates Coverage on Accurexa Inc.
ACCESSWIRE - Thu Jan 22, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / January 22, 2015 / Arrowhead Business and Investment Decisions, LLC ("Arrowhead"
initiated coverage and published a Due Diligence and Valuation Report on Accurexa Inc. ("Accurexa" or the "Company" (OTCQB:ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, on December 23, 2014. Accurexa Announces Appointment of Daniel A. Lim MD, PhD to its Scientific Advisory Board
ACCESSWIRE - Tue Jan 13, 7:00AM CST
SAN FRANCISCO, CA / ACCESSWIRE / January 13, 2015 / Accurexa Inc. (the "Company"
(OTCQB: ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today the appointment of Daniel A. Lim MD, PhD to its newly formed Scientific Advisory Board. The Scientific Advisory Board will work closely with the Company's management in the development of novel neurological therapies based on the Company's proprietary BranchPoint technology delivering therapeutics directly into specific regions of the brain. Accurexa to Present at 2014 Stem Cell Meeting on the Mesa
ACCESSWIRE - Mon Sep 29, 7:00AM CDT
San Francisco, California / ACCESSWIRE / September 29, 2014 / Accurexa Inc. (the "Company"
(OTCQB: ACXA) announced today that George Yu, the Company's President & CEO, will co-present with Daniel Lim, M.D., Ph.D., Assistant Professor of Neurological Surgery, University of California, San Francisco (UCSF) at the 4th Annual Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, CA. Accurexa Announces Exclusive License Agreement With Uc San Francisco
ACCESSWIRE - Wed Sep 17, 8:16AM CDT
SAN FRANCISCO, CA / ACCESSWIRE / September 17, 2014 / Accurexa Inc. (the "Company"
(OTCQB: ACXA) announced today that it has entered into an exclusive license agreement (the "UCSF License" with the University of California, San Francisco ("UCSF" in regards to the exclusive global licensing of a medical stereotactic device (the "UCSF device" , which the Company believes has the potential to significantly improve the delivery of stem cells into the human brain and enhance the efficacy of a wide range of stem cell therapeutics. Beyond stem cells, the platform technology of the UCSF device can also enable the delivery of cell-based therapeutics, gene therapies, and traditional drugs and drug infusions into the human brain. 
